Crossbow Therapeutics is a Cambridge, Massachusetts biotechnology company building a new class of cancer immunotherapies. Its T-Bolt platform engineers TCR-mimetic antibodies - T-cell engagers that recognize tiny peptide fragments displayed on a cancer cell's surface (peptide-HLA complexes), opening up intracellular proteins that conventional antibodies cannot reach. The lead program, CBX-250, is a first-in-class T-cell engager in a Phase 1 trial for relapsed or refractory myeloid malignancies. Backed by more than $157M in venture funding, Crossbow aims to expand the universe of targetable cancer antigens.
Sean McCarthy is the chairman, president and CEO of CytomX Therapeutics, a clinical-stage biopharma in South San Francisco building 'Probody' conditionally activated antibodies that switch on inside the tumor and stay quiet everywhere else. An Oxford-trained cancer biologist turned operator, he has run CytomX since 2011, taking it from a venture-backed startup to a Nasdaq-listed company with partnerships across Bristol Myers Squibb, AbbVie, Amgen, Astellas, Moderna and Regeneron.